Gastrointestinal cancer: Novel promising first-line combination
Gastrointestinal cancer: Novel promising first-line combination, Published online: 23 January 2018; doi:10.1038/nrclinonc.2018.7Gastrointestinal cancer: Novel promising first-line combination (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - January 23, 2018 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
Prostate cancer: CTCs enable early prediction of response
Prostate cancer: CTCs enable early prediction of response, Published online: 23 January 2018; doi:10.1038/nrclinonc.2018.5Prostate cancer: CTCs enable early prediction of response (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - January 23, 2018 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
Exogenous reproductive hormone use in breast cancer survivors and previvors
Exogenous reproductive hormone use in breast cancer survivors and previvors, Published online: 23 January 2018; doi:10.1038/nrclinonc.2017.207The safety of elective exogenous hormonal exposure among breast cancer survivors or women at high risk of having the disease has been debated for decades. Herein, the authors discuss the available data and present clinical recommendations regarding four areas of potential exogenous exposure to hormones: hormonal contraception; systemic hormone-replacement therapy; localized hormone-replacement therapy; and hormonal manipulation for fertility preservation or enhancement. Further resea...
Source: Nature Clinical Practice Oncology - January 23, 2018 Category: Cancer & Oncology Authors: Ines Vaz-Luis Ann H. Partridge Source Type: research
Kidney cancer: PBRM1 loss promotes tumour response to immunotherapy
Kidney cancer: PBRM1 loss promotes tumour response to immunotherapy, Published online: 23 January 2018; doi:10.1038/nrclinonc.2018.12Kidney cancer: PBRM1 loss promotes tumour response to immunotherapy (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - January 23, 2018 Category: Cancer & Oncology Authors: Grant Otto Source Type: research
Colorectal cancer: Genomic landscape of mCRC revealed
Colorectal cancer: Genomic landscape of mCRC revealed, Published online: 23 January 2018; doi:10.1038/nrclinonc.2018.10Colorectal cancer: Genomic landscape of mCRC revealed (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - January 23, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
Haematological cancer: Improved sensitivity in MRD detection
Haematological cancer: Improved sensitivity in MRD detection, Published online: 23 January 2018; doi:10.1038/nrclinonc.2018.6Haematological cancer: Improved sensitivity in MRD detection (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - January 23, 2018 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
Corrigendum: Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges
Corrigendum: Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges, Published online: 23 January 2018; doi:10.1038/nrclinonc.2018.13Corrigendum: Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - January 23, 2018 Category: Cancer & Oncology Authors: Conor A. Bradley Manuel Salto-Tellez Pierre Laurent-Puig Alberto Bardelli Christian Rolfo Josep Tabernero Hajrah A. Khawaja Mark Lawler Patrick G. Johnston Sandra Van Schaeybroeck on behalf of the MErCuRIC consortium Source Type: research
Notes from 2017, hopes for 2018
Notes from 2017, hopes for 2018, Published online: 22 January 2018; doi:10.1038/nrclinonc.2018.4Notes from 2017, hopes for 2018 (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - January 22, 2018 Category: Cancer & Oncology Source Type: research
Kidney cancer: First-in-class HIF2α antagonist safe and effective
Kidney cancer: First-in-class HIF2α antagonist safe and effective, Published online: 16 January 2018; doi:10.1038/nrclinonc.2018.3Kidney cancer: First-in-class HIF2α antagonist safe and effective (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - January 16, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
Haematological cancer: Daratumumab proves effective in patients with newly diagnosed multiple myeloma
Haematological cancer: Daratumumab proves effective in patients with newly diagnosed multiple myeloma, Published online: 16 January 2018; doi:10.1038/nrclinonc.2018.1Haematological cancer: Daratumumab proves effective in patients with newly diagnosed multiple myeloma (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - January 16, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
Will a global fund for cancer be the answer?
Will a global fund for cancer be the answer?, Published online: 16 January 2018; doi:10.1038/nrclinonc.2017.211A call for action has been made for the establishment of a global fund for cancer control, but potential donors have not reacted yet, possibly because this task would require an annual expenditure of billions of dollars. Herein, I suggest a less onerous starting point: targeting childhood cancer in Africa guided by well-designed national cancer control plans. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - January 16, 2018 Category: Cancer & Oncology Authors: Cristina Stefan Source Type: research
CNS cancer: TTFields improve survival
CNS cancer: TTFields improve survival, Published online: 16 January 2018; doi:10.1038/nrclinonc.2018.2CNS cancer: TTFields improve survival (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - January 16, 2018 Category: Cancer & Oncology Authors: David Killock Source Type: research
The bone-marrow niche in MDS and MGUS: implications for AML and MM
The bone-marrow niche in MDS and MGUS: implications for AML and MM, Published online: 09 January 2018; doi:10.1038/nrclinonc.2017.197Both multiple myeloma and acute myeloid leukaemia are often preceded by defined precursor stages of neoplasia, which can aid efforts to unravel the mechanisms of disease progression. Herein, the authors review studies of the important roles of microenvironmental factors in promoting the development and progression of haematological cancers in these precursor conditions. Potential therapeutic strategies targeting the abnormal bone-marrow microenvironment are discussed. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - January 9, 2018 Category: Cancer & Oncology Authors: Irene M. Ghobrial Alexandre Detappe Kenneth C. Anderson David P. Steensma Source Type: research
Determinants and clinical implications of chromosomal instability in cancer
Determinants and clinical implications of chromosomal instability in cancer, Published online: 03 January 2018; doi:10.1038/nrclinonc.2017.198Aberrant chromosomal architecture is one of the most common features of cancer and can often lead to chromosomal instability (CIN). In this Review, the authors describe the role of CIN in the development and progression of cancer and the potential to target the therapeutic vulnerabilities created by this process. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - January 3, 2018 Category: Cancer & Oncology Authors: Laurent Sansregret Bart Vanhaesebroeck Charles Swanton Source Type: research
Haematological cancer: Favourable outcomes with CAR T cells
Haematological cancer: Favourable outcomes with CAR T cells, Published online: 03 January 2018; doi:10.1038/nrclinonc.2017.208Haematological cancer: Favourable outcomes with CAR T cells (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - January 3, 2018 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
